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PREPARING COMPANIES FOR SUCCESS
Funding alone is frequently insufficient for earlystage small businesses developing biomedical products to achieve the appropriate milestones that will result in private sector follow-on funding. The NHLBI provides a suite of resources to assist companies that includes comprehensive customer-discovery programs, webinars focused on specific topics, and full-time staff available to provide expert advice on regulatory, business development, intellectual property, and entrepreneurship issues.
One of the major challenges facing all early-stage companies is understanding their customers, value proposition, and path to market. Small businesses developing biomedical products must also understand The small business set-aside has increased for both SBIR and STTR and will reach 3.2% and 0.45%, respectively, in fiscal year 2017. SBIR ¼ Small Business Innovation Research; Funding support mechanisms are shown in green; educational and commercialization assistance programs are shown in pink; National Heart, Lung, and Blood Institute (NHLBI) staff with business expertise are shown in blue. The program is designed to act like a funnel, starting with a large number of early-stage projects with little or no preliminary data that gradually advance through successive rounds of peer review to receive more funding. An individual project can receive $5 million or more over a 5-year period. In addition to funding, NHLBI provides resources and expertise to assist companies in advancing projects to the point they can be sustained in the private sector and ultimately commercialized to benefit patients and public health. FDA ¼ Food and Drug Administration; NIH ¼ National Institutes of Health; R&D ¼ research and development; other abbreviations as in Figure 1 .
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HAND-OFF TO THE PRIVATE SECTOR
The primary goal of the NHLBI small business program is to provide funding and resources to help The National Heart, Lung, and Blood Institute (NHLBI) supports a wide range of technologies at all stages of development.
IT ¼ information technology. Principle investigator must be >50% employed by the small business.
Formal cooperative R&D effort is between the small business and a U.S. research institution.
Small businesses majority owned by multiple VCs, hedge funds, or private equity firms are eligible to apply.
The small business must do a minimum of 40% of the work; research institution must do a minimum or 30% of the work.
Principle investigator may be primarily employed by either the small business or the research institution.
companies reach the key milestones that will enable them to transition to private sector support so they can ultimately bring new products to market to benefit patients and public health. In addition to the Phase IIB program described in the preceding text, the institute has dedicated significant resources to assisting companies with this transition. In addition, the company is mentored on how to speak with potential investors and partners, and on their partnering strategy at the event. This mentoring process is routinely lauded by both participants and investors and is an example of our commitment to providing the key support beyond funding that is necessary to our portfolio companies' success. More information on showcase opportunities and coaching is available on our website (http://www.nhlbi.nih.
gov/research/funding/sbir/ric/index.htm). 
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